Oncology · Multiple MyelomaTrial Updatecompetitivemid-term

AbbVie Initiates Study on Surzetoclax for Relapsed/Refractory Multiple Myeloma

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

AbbVie28 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/23/2026, 12:31:17 AM

Assessment confidence: 66% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

AbbVie's trial of surzetoclax could significantly impact its competitive positioning in the multiple myeloma market, particularly against established therapies. Monitoring the trial's progress is crucial as positive outcomes may redefine treatment standards and market dynamics. Regulatory context from FDA (FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (ORIG)) supports the near-term read. Assessment grounded in 29 ranked evidence items (14 high-relevance).

Strategic Assessment

Success in this trial could strengthen AbbVie's market position in multiple myeloma, impacting competitive dynamics and treatment standards. The strongest clinical anchor is Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (ClinicalTrials.gov), sponsor/company relevance (merck); patient population match (refractory). In Oncology · Multiple Myeloma, 7 regulatory and 7 competitive items passed relevance filtering for AbbVie.

Competitive Pressure

Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (ORIG) (FDA). Regulatory pathway relevance (nda). The trial's outcomes will influence future regulatory submissions and approvals for surzetoclax, impacting its market entry timeline and labeling.

Key Risks

Elevated medium regulatory exposure for AbbVie could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If successful, surzetoclax could capture significant market share in the relapsed/refractory multiple myeloma segment, potentially increasing AbbVie's revenue and altering competitive strategies.
Bristol Myers Squibb document relevant to the signal.
Lead sponsor: AstraZeneca. This is an interventional, modular, open-label, multicenter study to primarily evaluate the safety and tolerability of AZD0120 in adult participants with multiple myeloma (MM).
Oncology · KRAS G12C NSCLC · Trial Update · Divarasib's positive results position it as a potential new standard of care, challenging the current market leaders sotorasib and adagrasib.
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications with postmarketing trials that have verified clinical benefit and for which traditional approval has been subsequently granted for the specific indication.

What Would Change This Assessment

This becomes more urgent if Monitor enrollment progress and initial safety data from the trial, particularly in the dose escalation phases.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
Verified Clinical Benefit | Cancer Accelerated Approvals
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Frutas Hortalizas del Sur S.A. Initiates Recall of Frozen GreenWise Organic IQF Blueberries Due to Potential E.
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Ongoing | Cancer Accelerated Approvals
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Merck); Patient population match (refractory)
FDA document
View source
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple My
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Novartis)
FDA document
View source
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Palliative Care Integration in Pediatric Oncology Phase 1 Clinical Trials
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study at Multiple Centers to Evaluate the Safety and Practicality of the Levita Magnetic Surgical System for Use in Laparoscopic Upper Gastrointestinal Surgeries.
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma
Bristol Myers Squibbhigh relevance
Sponsor/company relevance (Bristol Myers Squibb); Patient population match (refractory)
FDA document
View source
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma
Bristol Myers Squibbhigh relevance
Sponsor/company relevance (Bristol Myers Squibb); Patient population match (refractory)
FDA document
View source
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma
Bristol Myers Squibbhigh relevance
Sponsor/company relevance (Bristol Myers Squibb); Patient population match (refractory)
FDA document
View source
FDA Grants Priority Review for ABBVIE's BLA761460 (DECNUPAZ)
Humanexa Signalshigh relevance
Entity match (abbvie)
Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Humanexa Signalsmedium relevance
Sponsor/company relevance (Roche)
Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Humanexa Signalsmedium relevance
Sponsor/company relevance (Roche)
Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalsmedium relevance
Sponsor/company relevance (Roche)

Effectiveness and safety of brentuximab vedotin-containing regimen versus standard chemotherapy in relapsed or refractory Hodgkin lymphoma: a multicenter cohort study.
PubMedhigh relevance
Patient population match (refractory)
FDA document
View source
Comparison of epcoritamab, lenalidomide, and rituximab versus usual care in relapsed/refractory follicular lymphoma.
PubMedhigh relevance
Patient population match (refractory)
FDA document
View source
An unanchored matching-adjusted indirect comparison of the efficacy of zanubrutinib versus ibrutinib for the treatment of relapsed/refractory mantle-cell lymphoma.
PubMedhigh relevance
Patient population match (refractory)
FDA document
View source
RBMS1 enhances PDPK1 mRNA stability to promote multiple myeloma malignancy and M2 macrophage polarization.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Elranatamab: A novel B-cell maturation T-cell engager.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Novel multiplex immunofluorescence-based tumor inflammation score provides apparent predictive biomarker in a phase I/II study of pembrolizumab with gemcitabine in patients with previously-treated adv
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

AbbVie
daratumumab

Commercial impact

high

If successful, surzetoclax could capture significant market share in the relapsed/refractory multiple myeloma segment, potentially increasing AbbVie's revenue and altering competitive strategies.

Regulatory impact

medium

The trial's outcomes will influence future regulatory submissions and approvals for surzetoclax, impacting its market entry timeline and labeling.

What to watch

Monitor enrollment progress and initial safety data from the trial, particularly in the dose escalation phases.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.